263 related articles for article (PubMed ID: 33125143)
1. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
2. Targeting BRD4 proteins suppresses the growth of NSCLC through downregulation of eIF4E expression.
Gao Z; Yuan T; Zhou X; Ni P; Sun G; Li P; Cheng Z; Wang X
Cancer Biol Ther; 2018 May; 19(5):407-415. PubMed ID: 29333921
[TBL] [Abstract][Full Text] [Related]
3. miR-33a inhibits cell growth in renal cancer by downregulation of MDM4 expression.
Jiang K; Sun F; Zhu J; Luo G; Ban Y; Zhang P
Mol Genet Genomic Med; 2019 Aug; 7(8):e833. PubMed ID: 31250570
[TBL] [Abstract][Full Text] [Related]
4. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
5. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability.
Tang J; Wang F; Cheng G; Si S; Sun X; Han J; Yu H; Zhang W; Lv Q; Wei JF; Yang H
J Exp Clin Cancer Res; 2018 Feb; 37(1):40. PubMed ID: 29482572
[TBL] [Abstract][Full Text] [Related]
6. Long noncoding RNA TUG1 promotes cell proliferation and migration of renal cell carcinoma via regulation of YAP.
Liu S; Yang Y; Wang W; Pan X
J Cell Biochem; 2018 Dec; 119(12):9694-9706. PubMed ID: 30132963
[TBL] [Abstract][Full Text] [Related]
7. Long non‑coding RNA MALAT1 correlates with cell viability and mobility by targeting miR‑22‑3p in renal cell carcinoma via the PI3K/Akt pathway.
Li Z; Ma Z; Xu X
Oncol Rep; 2019 Feb; 41(2):1113-1121. PubMed ID: 30431104
[TBL] [Abstract][Full Text] [Related]
8. Silencing Livin induces apoptotic and autophagic cell death, increasing chemotherapeutic sensitivity to cisplatin of renal carcinoma cells.
Wang Z; Liu S; Ding K; Ding S; Li C; Lu J; Gao D; Zhang T; Bi D
Tumour Biol; 2016 Nov; 37(11):15133-15143. PubMed ID: 27677286
[TBL] [Abstract][Full Text] [Related]
9. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
11. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
[TBL] [Abstract][Full Text] [Related]
12. Methylation-mediated miR-214 regulates proliferation and drug sensitivity of renal cell carcinoma cells through targeting LIVIN.
Xu H; Wu S; Shen X; Shi Z; Wu D; Yuan Y; Jiang W; Wang Q; Ke Q; Mao Q; Li X; Liu Y; Yuan P; Zhang Q; Huang E; Chen X
J Cell Mol Med; 2020 Jun; 24(11):6410-6425. PubMed ID: 32395888
[TBL] [Abstract][Full Text] [Related]
13. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
14. EIF3D promotes sunitinib resistance of renal cell carcinoma by interacting with GRP78 and inhibiting its degradation.
Huang H; Gao Y; Liu A; Yang X; Huang F; Xu L; Danfeng X; Chen L
EBioMedicine; 2019 Nov; 49():189-201. PubMed ID: 31669222
[TBL] [Abstract][Full Text] [Related]
15. GSK-3 directly regulates phospho-4EBP1 in renal cell carcinoma cell-line: an intrinsic subcellular mechanism for resistance to mTORC1 inhibition.
Ito H; Ichiyanagi O; Naito S; Bilim VN; Tomita Y; Kato T; Nagaoka A; Tsuchiya N
BMC Cancer; 2016 Jul; 16():393. PubMed ID: 27387559
[TBL] [Abstract][Full Text] [Related]
16. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma.
Liu Y; Cheng G; Huang Z; Bao L; Liu J; Wang C; Xiong Z; Zhou L; Xu T; Liu D; Yang H; Chen K; Zhang X
Cell Death Dis; 2020 Jul; 11(7):515. PubMed ID: 32641718
[TBL] [Abstract][Full Text] [Related]
17. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma.
Sitaram RT; Cairney CJ; Grabowski P; Keith WN; Hallberg B; Ljungberg B; Roos G
Int J Cancer; 2009 Aug; 125(4):783-90. PubMed ID: 19384955
[TBL] [Abstract][Full Text] [Related]
18. miR-1293 Suppresses Tumor Malignancy by Targeting Hydrocyanic Oxidase 2: Therapeutic Potential of a miR-1293/Hydrocyanic Oxidase 2 Axis in Renal Cell Carcinoma.
Liu XL; Pan WG; Li KL; Mao YJ; Liu SD; Zhang RM
Cancer Biother Radiopharm; 2020 Jun; 35(5):377-386. PubMed ID: 31971830
[TBL] [Abstract][Full Text] [Related]
19. The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies.
Stubbs MC; Burn TC; Sparks R; Maduskuie T; Diamond S; Rupar M; Wen X; Volgina A; Zolotarjova N; Waeltz P; Favata M; Jalluri R; Liu H; Liu XM; Li J; Collins R; Falahatpisheh N; Polam P; DiMatteo D; Feldman P; Dostalik V; Thekkat P; Gardiner C; He X; Li Y; Covington M; Wynn R; Ruggeri B; Yeleswaram S; Xue CB; Yao W; Combs AP; Huber R; Hollis G; Scherle P; Liu PCC
Clin Cancer Res; 2019 Jan; 25(1):300-311. PubMed ID: 30206163
[TBL] [Abstract][Full Text] [Related]
20. Upregulated expression of eIF3C is associated with malignant behavior in renal cell carcinoma.
Fan M; Wang K; Wei X; Yao H; Chen Z; He X
Int J Oncol; 2019 Dec; 55(6):1385-1395. PubMed ID: 31638200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
